Trinity Biotech Plc (TRIB) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Trinity Biotech Plc  (NASDAQ: TRIB)


Trinity Biotech Plc's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Trinity Biotech Plc's ROI in the fourth quarter of 2025?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Trinity Biotech Plc's return on investment (ROI) in its fourth quarter of 2025

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM - - - -46.46 % 51.5 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions -36 -36 -36 -36 -31
Return On Investment (TTM) - - - - -
TRIB's Overall Ranking # # # # #
Seq. Investment Change TTM - - - -57.03 % -4.52 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -37 -31 -31 -31 -31

TRIB Company Profile >> Back to TRIB Roi Comparisons >> See Annual TRIB Return On Investment



Return On Investment TRIB's Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Investment Statistics
High Average Low
0 %
0 %
0 %
 



  News about Trinity Biotech Plc Return on Investment ROI

Trinity Biotech's Strategic Application for Early Sjogren's Syndrome Test Panel PLA Code Aims to Turn Around Financial Performance and Expand Market Reach

February 7, 2024



Trinity Biotech Plc, a leading healthcare company, has recently announced that its New York-based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjogren s Syndrome Test Panel. This strategic move aims to enhance market access and increase profitability for the company. However, it comes amidst Trinity Biotech s recorded net loss and a declining return on investment (ROI) during the fourth quarter of 2022.
Facts:
1. Trinity Biotech s New York-based reference laboratory, Immco Diagnostics, has applied for a PLA code for its Early Sjogren s Syndrome Test Panel.
2. The application is expected to facilitate an optimized market access strategy for broader patient access and improved profitability.
3. Trinity Biotech Plc recorded a cumulative net loss of $-41 million during the 12 months ending in the fourth quarter of 2022.
4. This negative net loss created a negative ROI of -54.84% for the company.
5. Among 683 companies in the healthcare sector, Trinity Biotech had a lower ROI compared to others.
6. The company s overall ranking in terms of ROI deteriorated from 0 to 4631 in the third quarter of 2022.

Trinity Biotech Implements Strategic Leadership Shake-Up to Revitalize Stock Performance and Drive Growth.

December 18, 2023



Trinity Biotech, a leading global provider of diagnostic solutions, has recently made significant changes to its management team. The company announced that John Gillard has been appointed as the new Chief Executive Officer (CEO), bringing with him a wealth of experience and expertise. In addition, Des Fitzgerald has been named as the Interim Chief Financial Officer (CFO), ensuring smooth financial management during this transition period.
The appointment of John Gillard as the CEO marks an exciting new chapter for Trinity Biotech. With a proven track record of success in the healthcare industry, Gillard brings a fresh perspective and strategic vision to the company. His leadership skills and deep understanding of the diagnostic solutions market are sure to drive Trinity Biotech towards continued growth and innovation.





Financial Statements
Trinity Biotech Plc's IV. Quarter Investments $ -36 Millions TRIB's Balance sheet
Trinity Biotech Plc's IV. Quarter Income $ -37 Millions Quarterly TRIB's Income Statement
TRIB's Income by Division See TRIB's Income by Division


TRIB Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions -36 -31 -22 75 18
Y / Y Investment Growth - - - 306.24 % -61.1 %
Net Income in Millions -37 -31 -37 -44 -2
Y / Y Net Income Growth - - - - -
Annual Return On Investment - - - -58.3 % -10.05 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
TRIB's Roi Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for TRIB's Competitors
Subscribers only: Roi for Trinity Biotech Plc's Suppliers
Subscribers only: Return On Investment for TRIB's Customers

Other Ratios
TRIB's Roa TRIB's Inventory Turnover Ratio TRIB's Growth Rates TRIB's Dividend Statistics
TRIB's Profitability Ratios TRIB's Asset Turnover Ratio TRIB's Dividend Growth
TRIB's Roe TRIB's Valuation Ratios TRIB's Financial Strength Ratios TRIB's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Oncotelic Therapeutics Inc   252.91 %
Atara Biotherapeutics Inc   242.55 %
Traws Pharma inc   234.73 %
Scisparc Ltd  234.01 %
Petros Pharmaceuticals inc   233.39 %
Omada Health Inc   200.69 %
Interpace Biosciences Inc   198.59 %
Rigel Pharmaceuticals Inc  185.38 %
Icecure Medical Ltd  166.12 %
Silexion Therapeutics Corp  142.64 %
Heartflow Inc   142.09 %
Capforce Inc   140.91 %
Check Cap Ltd  120.45 %
Coherus Oncology inc   119.44 %
Kyntra Bio Inc   118.89 %
Lifemd Inc   105.75 %
Biocryst Pharmaceuticals Inc   88.36 %
Advanced Biomed Inc.  84.64 %
Earth Science Tech Inc   78.43 %
Exelixis Inc   71.31 %
Entera Bio Ltd   63.91 %
Tg Therapeutics Inc   63.77 %
Aurinia Pharmaceuticals Inc   56.37 %
Pulmatrix Inc   53.09 %
Novavax inc   51.88 %
Q32 Bio Inc   50.33 %
Idexx Laboratories Inc  48.69 %
Theravance Biopharma inc   46.03 %
Elite Pharmaceuticals Inc   45.80 %
Enlivex Therapeutics Ltd  45.75 %

Date modified: 2026-07-07T13:58:52+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.